UspA2 protein constructs and uses thereof
AssigneeGlaxosmithkline Biologicals SA
InventorsNormand Blais, Cindy Castado, Patrick Chomez, Marianne Dewerchin
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions comprising Moraxella catarrhalis (M. catarrhalis) Ubiquitous surface protein A2 (UspA2). More particularly, the present application relates to UspA2 protein constructs and immunogenic compositions comprising the constructs, vaccines comprising such immunogenic compositions and therapeutic uses of the same. The invention further relates to compositions comprising UspA2 in combination with at least one antigen from Haemophilus influenzae, immunogenic compositions comprising the antigens, vaccines comprising such immunogenic compositions and therapeutic uses of the same.
Claims12
An immunogenic composition comprising SEQ ID NO. 69.
A method for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in a subject in need thereof comprising administering to said subject a therapeutically effective amount of an immunogenic composition comprising 10 μg of protein D from Haemophilus influenzae, 10 μg of PEPiIA fusion protein LVL735, 3.3 μg of UspA2 MC009, and adjuvant AS01E.
Dependencies are inferred from the claim text.